Previous 10 | Next 10 |
- Demonstrated dramatic reduction in proptosis, or eye bulging, the main cause of morbidity in TED - - There are no FDA-approved treatments available for TED, a devastating rare eye disease that affects 15,000 to 20,000 people each year in the United States - - Continue to expect ...
Horizon Pharma plc (HZNP) Q4 2018 Earnings Conference Call February 27, 2019 08:00 AM ET Company Participants Tina Ventura - Senior Vice President of Investor Relations Timothy Walbert - Chairman, President and Chief Executive Officer Paul Hoelscher - Executive Vice President and...
Gevo (NASDAQ: GEVO ) +24% on entering into a long-term agreement with HCS group. More news on: Gevo, Inc., Tandem Diabetes Care, Inc., Versum Materials, Stocks on the move, Read more ...
Horizon Pharma ( HZNP ) Q4 results : Revenues: $355.5M (+29.6%). More news on: Horizon Pharma plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
The following slide deck was published by Horizon Pharma plc in conjunction with their 2018 Q4 earnings Read more ...
Horizon Pharma (NASDAQ: HZNP ): Q4 Non-GAAP EPS of $0.67 beats by $0.13 ; GAAP EPS of $0.50 beats by $0.71 . More news on: Horizon Pharma plc, Earnings news and commentary, Healthcare stocks news, Read more ...
-- Fourth-Quarter 2018 Net Sales Increased 30 Percent to $355.5 Million Driven by 33 Percent Growth in Orphan and Rheumatology Segment; Fourth-Quarter 2018 GAAP Net Income of $87.6 Million; Adjusted EBITDA of $151.1 Million -- -- Full-Year 2018 Net Sales Increased 14 Percent to $1.2...
AES , AMRN , AMT , ANIP , BBY , CHK , CLH , CPB , DF , DNR , DOC , DY , EYE , FTDR , GCP , GTE , HMLP , HPT , HZNP , IONS , LIVN , LOW , LXP , MDCO , MGPI , MIDD , NEWM , NOVT , OCN , ODP , PEG , PGTI , PNM , RDC , SBGI , SHOO , TAST , TJX , UTHR F...
Horizon Pharma plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in March: Cowen and Company 39 th Annual Health Care Conference Date: March 11, 2019 Presentation Time: 12 p.m. ET Location: Boston The confer...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...